Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 981

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Open access
Mössner, Ekkehard, Brünker, Peter, Moser, Samuel, Püntener, Ursula, Schmidt, Carla, Herter, Sylvia, Grau, Roger, Gerdes, Christian, Nopora, Adam, van Puijenbroek, Erwin, Ferrara, Claudia, Sondermann, Peter, Jäger, Christiane, Strein, Pamela, Fertig, Georg, Friess, Thomas, Schüll, Christine, Bauer, Sabine, Dal Porto, Joseph, Del Nagro, Christopher, Dabbagh, Karim, Dyer, Martin J. S., Poppema, Sibrand, Klein, Christian, Umaña, Pablo·2010·Blood
DOI 10.1182/blood-2009-06-225979
Open this paper in CoChat — free account

Abstract

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal antibodies against CD20, such as rituximab, has revolutionized the treatment of these disorders, greatly improving overall survival in patients. Here, we report the development of GA101 as the first Fc-engineered, type II humanized IgG1 antibody against CD20. Relative to rituximab, GA101 has increased direct and immune effector cell-mediated cytotoxicity and exhibits superior activity in cellular assays and whole blood B-cell depletion assays. In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival. In nonhuman primates, GA101 demonstrates superior B cell–depleting activity in lymphoid tissue, including in lymph nodes and spleen. Taken together, these results provide compelling evidence for the development of GA101 as a promising new therapy for the treatment of B-cell disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-06-225979

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 981

Metadata

Authors
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jäger, C., Strein, P., Fertig, G., Friess, T., Schüll, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M. J. S., Poppema, S., Klein, C., & Umaña, P.
Venue
Blood
Publisher
American Society of Hematology
Published
2010-06-03
Volume
115
Issue
22
Pages
4393-4402
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2009-06-225979
OpenAlex
W2091057822
Cited by
981
References
33
FWCI
44.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. https://app.cochat.ai/papers/10.1182/blood-2009-06-225979
The paper
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jäger, C., Strein, P., Fertig, G., Friess, T., Schüll, C., Bauer, S., Dal Porto, J., . . . Umaña, P. (2010). Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. https://doi.org/10.1182/blood-2009-06-225979

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.